震裕科技(300953.SZ):擬對震裕銷售增資3億元
格隆匯2月20日丨震裕科技(300953.SZ)公佈,爲進一步優化公司全資子公司寧波震裕銷售有限公司(簡稱“震裕銷售”)的資本結構,降低其資產負債率,保障震裕銷售的可持續發展,完善公司戰略發展規劃,公司於2025年2月20日召開第五屆董事會第三次會議,以9票同意,0票反對,0票棄權的表決結果審議通過《關於對全資子公司增資的議案》,公司擬使用自有資金對全資子公司震裕銷售增資3億元人民幣。本次增資後,震裕銷售註冊資本由人民幣5,000.00萬元增加至人民幣35,000.00萬元,公司仍持有震裕銷售100%股權,震裕銷售仍爲公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.